文献速递乳房整形与再造创面修复

免疫检查点抑制剂肺炎对乳腺癌确定性再造的影响

Immune Checkpoint Inhibitor Pneumonitis: Implications for Definitive Breast Cancer Reconstruction.
PubMed 文献 · Ann Plast Surg · 2026-01-30

本病例报告描述一名59岁BRCA阳性三阴性乳腺癌患者,在完成帕博利珠单抗治疗1个多月后行双侧腹部游离皮瓣乳房再造,术后出现呼吸功能恶化并诊断为免疫检查点抑制剂肺炎(CIP)。经皮质类固醇、IVIG和MMF联合治疗后恢复,术后第15天带鼻导管吸氧出院,随访仅需室内空气且再造效果良好。

要点

  • 乳腺癌再造术前接受ICI治疗者,术后呼吸恶化需警惕CIP。
  • CIP诊断需排除肺栓塞、肺炎等术后常见病因,影像学支持。
  • 皮质类固醇、IVIG和MMF联合治疗可使CIP患者恢复。

核心结论

  • 接受ICI治疗的乳腺癌患者行再造手术时,围手术期需警惕CIP这一罕见但可能危及生命的免疫相关不良事件。

研究设计与样本

  • 病例报告:1例59岁BRCA阳性三阴性乳腺癌患者,双侧乳房切除术后行双侧腹部游离皮瓣乳房再造。

主要发现

  • 患者在完成帕博利珠单抗治疗1个多月后手术,术后呼吸功能恶化至静息时依赖高流量鼻导管。
  • 排除肺栓塞、肺炎等病因后,影像学支持诊断为CIP。
  • 经皮质类固醇、IVIG和MMF联合治疗后恢复,术后第15天带鼻导管吸氧出院,随访仅需室内空气且再造效果良好。

临床怎么用

  • 乳腺癌及再造外科医生应了解CIP,尤其对接受个性化免疫调节化疗方案的患者,需关注再造手术时机与围手术期管理。

局限性

  • 单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Checkpoint inhibitor-associated pneumonitis (CIP) is a rare but potentially life-threatening immune-related adverse event in patients receiving immunotherapy. Its occurrence especially in the immediate postoperative period following major reconstructive breast surgery has not been previously described and poses unique diagnostic and management challenges.We report the case of a 59-year-old BRCA+ female with history of right-sided triple-negative breast cancer status-post bilateral mastectomy with negative right sentinel lymph node biopsy who had undergone bilateral abdominal based free flap breast reconstruction over 1 month after the completion of pembrolizumab, an immune checkpoint inhibitor (ICI). This patient subsequently had worsening postoperative respiratory function to the point of being high-flow nasal cannula dependent on rest. Appropriate postoperative etiologies (i.e., pulmonary embolism, pneumonia, etc) were ruled out, and CIP was diagnosed with supporting imaging. The patient recovered with a treatment combination of corticosteroids, IVIG, and MMF, and the patient was discharged home on supplemental oxygen via nasal cannula on postoperative day 15. She has since followed up only on room air and excellent postreconstructive outcomes.This case report underscores a highly surgically relevant topic of breast cancer reconstructive surgery timing and clinical management of those patients treated with ICI. Especially with personalized immunomodulator chemotherapy regimens becoming more prevalent, breast and reconstructive surgeons, alike, should be aware of this likely growing phenomenon of CIP.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Sharma SB, Tepe SM, Fedor CJ, et al. Immune Checkpoint Inhibitor Pneumonitis: Implications for Definitive Breast Cancer Reconstruction. Ann Plast Surg. 2026. PMID: 41616249. doi:10.1097/SAP.0000000000004655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。